^Heck HA, Buttrill SE, Flynn NW, Dyer RL, Anbar M, Cairns T, et al. Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests. Journal of Pharmacokinetics and Biopharmaceutics. June 1979, 7 (3): 233–248. PMID 480146. S2CID 23232584. doi:10.1007/BF01060015.
^Robert R, Blakeney PE, Villarreal C, Rosenberg L, Meyer WJ. Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry. July 1999, 38 (7): 873–882. PMID 10405506. doi:10.1097/00004583-199907000-00018.
^Tcheung WJ, Robert R, Rosenberg L, Rosenberg M, Villarreal C, Thomas C, et al. Early treatment of acute stress disorder in children with major burn injury. Pediatric Critical Care Medicine. November 2005, 6 (6): 676–681. PMID 16276335. S2CID 43261789. doi:10.1097/01.pcc.0000165562.04157.da.
^Robert R, Tcheung WJ, Rosenberg L, Rosenberg M, Mitchell C, Villarreal C, et al. Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: a randomized, double-blind study. Burns. November 2008, 34 (7): 919–928. PMID 18675519. doi:10.1016/j.burns.2008.04.009.